TORONTO, May 17, 2018 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”) (TSX Venture:RX) will be
reporting its financial results for the first quarter ended March 31, 2018 on Wednesday, May 30, 2018. A presentation on the
Company’s first quarter 2018 results by René Goehrum, BioSyent President and CEO, will also be available on the Company’s website
on the date of release.
About BioSyent Inc.
Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent is a profitable growth-oriented
specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that
have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients.
BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, hospital
and international business units.
As of the date of this press release, the Company has 14,509,095 common shares issued and outstanding.
For a direct market quote for the TSX Venture Exchange and other Company financial information please visit
www.tmxmoney.com.
For further information please contact:
Mr. René C. Goehrum
President and CEO
BioSyent Inc.
Tel: (905) 206-0013
E-Mail: investors@biosyent.com
Web: www.biosyent.com
This press release may contain information or statements that are forward-looking. The contents herein
represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or
outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not
limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining
regulatory approvals.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies
of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
